The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of ARV-806, a PROTAC KRAS G12D degrader, in KRAS G12D–mutated advanced solid tumors, including pancreatic cancer.
 
Yonina Murciano-Goroff
Employment - Memorial Sloan Kettering Cancer Center (MSK has institutional financial interests relative to Elucida Oncology); Memorial Sloan-Kettering Cancer Center
Honoraria - Amgen; Virology Education
Consulting or Advisory Role - Abbvie; Revolution Medicines
Research Funding - Abbvie (Inst); Andrew Sabin Family Foundation; Arvinas (Inst); Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Conquer Cancer, the ASCO Foundation; Druckenmiller Center for Lung Cancer Research; E.R. Squibb Sons, LLC; Elucida Oncology (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); Erasca, Inc (Inst); Erasca, Inc (Inst); Hengrui Pharmaceutical (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Loxo Oncology / Eli Lilly (Inst); Loxo Oncology / Eli Lilly (Inst); Loxo/Lilly (Inst); Luzsana Biotechnology (Inst); Mirati Therapeutics (Inst); National Cancer Institute; National Cancer Institute; National Institutes of Health (NIH)/National Cancer Institute (NCI); Squeri Grant for Drug Development; Taiho Oncology (Inst); The Society of Memorial Sloan Kettering
Patents, Royalties, Other Intellectual Property - Rutgers University Press; Wolters Kluwer
Travel, Accommodations, Expenses - AstraZeneca; Loxo Oncology/ Eli Lilly
Other Relationship - Abbvie; Amgen; Arvinas; AstraZeneca; Endeavor Biomedicines; Loxo Oncology/ Eli Lilly; Taiho Pharmaceutical
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Actuate Therapeutics; Agenus; Amgen; Atreca; Boehringer Ingelheim; Cullinan Oncology; DAAN Biotherapeutics; EMD Serono; GlaxoSmithKline; I-Mab; Kineta; Kyowa Kirin International; Mekanistic Therapeutics; Pfizer; Prelude Therapeutics; Quanta Therapeutics; Schrodinger; Sotio; Takeda; Wells Therapeutics; Zai Lab
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Arvinas; Genentech; Merck KGaA; Pfizer
 
Ignacio Garrido-Laguna
Consulting or Advisory Role - Abbvie; EcoR1 Capital; Fortvita; Guidepoint Global; Kestrel Therapeutics; KeyQuest Health; KeyQuest Health; Lilly; Quanta Therapeutics; Revolution Medicines; SOTIO
Research Funding - 280 BIO (Inst); ABM (Inst); Bayer (Inst); BridgeBio Pharma (Inst); Bristol-Myers Squibb (Inst); EcoR1 Capital; GlaxoSmithKline (Inst); Guidepoint Inc; Incyte (Inst); Jacobio (Inst); Kumquat Biosciences (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Pfizer (Inst); Quanta Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Tango Therapeutics (Inst); Tolero Pharmaceuticals (Inst); Yingli Pharma (Inst)
 
Benjamin Herzberg
Honoraria - Boxer Capital; Eisai; IDEOlogy Health; OncLive/MJH Life Sciences
Consulting or Advisory Role - Amgen; Arvinas; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi-Sankyo; IDEAYA Biosciences; Johnson and Johnson; Lilly
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca; IDEAYA Biosciences (Inst); Lilly (Inst); Monte Rosa Therapeutics (Inst); Nested Therapeutics (Inst); Prelude Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - DAVA Oncology
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Daiichi Sankyo, Inc.; Genentech/Roche (I); Gilead Sciences; HalioDx; Ionova; Janssen; Loxo; Merck; MERCK (I); Novartis; Pfizer; Pfizer; Quanta Therapeutics; Scorpion Therapeutics; Seagen; Silverback Therapeutics
Speakers' Bureau - Merck
Research Funding - 1200 Pharma (Inst); AADi (Inst); Abbvie (Inst); Alpine Immune Sciences (Inst); Ambrx (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); Arvinas (Inst); Astellas Pharma (Inst); BioNTech (Inst); BioTheryX (Inst); Bolt Biotherapeutics (Inst); Carrick Therapeutics (Inst); Compugen (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Ensem (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Infinity Pharmaceuticals (Inst); Institut de Recherches Internationales Servier (I.R.I.S) (Inst); Ionova (Inst); Ionova (Inst); Klus Pharma (Inst); KSQ Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Loxo@Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); MOMA Therapeutics (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Olema Oncology (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Pyrotec Therapeutics (Inst); Quanta Therapeutics (Inst); Roche (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seagen (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst); Vividion Therapeutics (Inst)
 
Neel Gandhi
Employment - Carolina Bio-Oncology Institute/Biocytics
Consulting or Advisory Role - CytomX Therapeutics (Inst)
 
Kathryn Smith
Employment - Arvinas
Stock and Other Ownership Interests - Arvinas
 
Lori Cykowski
Employment - Arvinas
Stock and Other Ownership Interests - Arvinas; Arvinas (I)
Travel, Accommodations, Expenses - Arvinas
 
Xin Zhi
Employment - Arvinas
Stock and Other Ownership Interests - ARVINAS
 
Diane Healey
Employment - Arvinas
Stock and Other Ownership Interests - Arvinas
 
Vaibhav Patel
Employment - Arvinas
Stock and Other Ownership Interests - Arvinas; crispr therapeutics; Exact Sciences; Iovance Biotherapeutics; Sellas Life Sciences; Sutro Biopharma; Syndax
 
David Hong
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - crossbridge Bio; MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - 280 Bio; Acuta; Acuta Capital Partners; Alphasights; Amgen; Amgen; Bain Capital; Bayer; Blueprint Medicines; Bluestar Genomics; Boxer Capital; Breakthrough Bio; Bristol Myers Squibb Company; Children's Oncology Group; COR2ed; Cowen Group In; Crossbridge Bio; EcoR1 Capital; Erasca, Inc; Gerson Lehrman Group; GroupH; Guidepoint Pharmacy; Immunogenesis; ImmunoGenesis; Janssen; Kestrel Therapeutics; Medacorp; Medscape; Orbi Capital; Pfizer; PharmaResearch; Remedy Inc; Revolution Medicines; Stipple Bio; T-Knife; TouchEd; Travistock Group; WebMD; WebMed; Xencor
Research Funding - 280 Bio; Abbvie (Inst); Adlai Nortye; Alterome Therapeutics; Amgen (Inst); Astellas Medivation; AstraZeneca; Bayer (Inst); BeiGene; BioBridge (Inst); Biomea Fusion (Inst); Bristol Myers Squibb (Inst); Chong Kun Dang Pharmaceutical; Deciphera Pharmaceuticals Inc. (Inst); E.R. Squibb & Sons LLC (Inst); Endeavor BioMedicines; Erasca, Inc; Exelixis (Inst); Genentech; Genentech (Inst); Immunogenesis; Incyte (Inst); InhibRx; KumQuat; Lilly; Merck Sharp & Dohme LLC (Inst); Mirati Therapeutics (Inst); National Cancer Institute; Pfizer (Inst); Quanta Therapeutics (Inst); Revolution Medicines; Roche; VM Pharma
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; BeiGene (I); Genmab; ImmunoGenesis; Medscape; Mirati Therapeutics; Society for Immunotherapy of Cancer; Telperian